|
|
|
|
|
|
|
25.06.26 - 12:39
|
ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement (GlobeNewswire EN)
|
|
|
LEIDEN, Netherlands and CAMBRIDGE, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (“ProQR”), a clinical-stage biotechnology company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the pricing of an underwritten registered direct offering of 27,624,310 ordinary shares (the “Offering”) at an offering price of $1.81 per share (the “Offering Price”), for total gross proceeds of approximately $50.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by ProQR....
|
|
|
|
|
|
|
30.04.26 - 14:03
|
ProQR Announces Nomination of Dr. Lykke Hinsch Gylvin to its Board of Directors (GlobeNewswire EN)
|
|
|
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 30, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the nomination of Lykke Hinsch Gylvin, MD, EMBA, Chief Medical Officer and Head of Global Medicine at Boehringer Ingelheim, to its Board of Directors....
|
|
|
|
|
|
|
|
|
|
|
|
|
12.03.26 - 12:03
|
ProQR Announces Year End 2025 Operating and Financial Results (GlobeNewswire EN)
|
|
|
LEIDEN, Netherlands & CAMBRIDGE, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today reported its financial and operating results for the year ended December 31, 2025, and provided a business update....
|
|
|
03.03.26 - 22:33
|
ProQR Announces Webcast of Presentation at the 2026 Citizens Life Sciences Conference (GlobeNewswire EN)
|
|
|
LEIDEN, Netherlands & CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary ADAR-mediated Axiomer™ RNA editing technology platform, today announced that company management will present at the Citizens Life Sciences Conference on Wednesday, March 11, 2026 at 3:25pm ET....
|
|
|
|
|
01.12.25 - 14:03
|
ProQR to Participate in 8th Annual Evercore Healthcare Conference (GlobeNewswire EN)
|
|
|
LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary ADAR-mediated Axiomer™ RNA editing technology platform, today announced that the Company will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Thursday, December 4, 2025 at 8:20am ET....
|
|
|
|
|
06.11.25 - 13:03
|
ProQR Announces Third Quarter 2025 Operating and Financial Results (GlobeNewswire EN)
|
|
|
LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today reported its financial and operating results for the third quarter ended September 30, 2025, and provided a business update....
|
|
|
20.10.25 - 14:03
|
ProQR Receives CTA Authorization for AX-0810 and Announces Virtual Investor and Analyst Event on November 3, 2025 (GlobeNewswire EN)
|
|
|
LEIDEN, Netherlands & CAMBRIDGE, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced that following review under the new European Medicines Agency (EMA) centralized review process, the Central Committee on Research Involving Human Subjects (CCMO) has authorized ProQR's Clinical Trial Application (CTA) for a Phase 1 study of AX-0810 in healthy volunteers. AX-0810 is the Company's lead investigational editing oligonucleotide (EON) targeting NTCP, which is being developed for the treatment of cholestatic diseases like primary sclerosing cholangitis and biliary atresia....
|
|
|
13.10.25 - 14:33
|
ProQR to Participate in Upcoming Investor Conferences in October 2025 (GlobeNewswire EN)
|
|
|
LEIDEN, Netherlands & CAMBRIDGE, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary ADAR-mediated Axiomer™ RNA editing technology platform, today announced that company management will participate in the following upcoming investor conferences: ...
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
